Nephronomics identifies novel genome-phenome associations within cardio-kidney-metabolic (CKM) diseases by analyzing comprehensive clinical and genomics data. The company leverages its proprietary Nephronomics Atlas, integrating whole genome sequencing with longitudinal phenotypic records, to refine renal disease categories. This precision approach enables patient stratification and supports the discovery and development of targeted next-generation therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic approaches for cardio-kidney-metabolic (CKM) diseases often rely on inconsistently applied laboratory criteria and may overlook significant genetic predispositions. This can lead to a lack of precise patient stratification and the development of targeted therapies, as kidney diseases are increasingly understood as complex conditions intertwined with cardiovascular and metabolic disorders. The genetic component of renal disease, potentially accounting for a substantial portion of non-diabetic kidney disease cases, remains underappreciated in clinical practice.
Solution
Nephronomics is a precision medicine company focused on developing targeted therapies for cardio-kidney-metabolic diseases. The company vertically integrates a comprehensive database of clinical and genomic data with advanced machine learning models to identify underlying molecular mechanisms driving these conditions. By reconceptualizing traditional renal disease categories and identifying clinically relevant subtypes, Nephronomics aims to improve patient stratification and treatment efficacy. This data-driven approach facilitates the discovery of novel genome-phenome associations that can inform the development of next-generation therapeutics.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies seeking to develop precision therapies for cardio-kidney-metabolic diseases, as well as researchers and clinicians focused on renal and cardiovascular medicine.
Features
- Nephronomics Atlas: A proprietary database integrating matched whole genome sequencing and longitudinal medical records from over 35,000 patients.
- Machine Learning Integration: Utilizes ML and computational biology tools to analyze unstructured EMR text, multi-omics data, and imaging data.
- Genetic Analysis: Focuses on identifying genome-phenome associations and genetic factors influencing renal disease progression and survival.
- Patient Stratification: Enables stratification of patients based on cardio-renal profiles to tailor therapeutic interventions.
- Drug Target Discovery: Leverages AI-powered analysis to uncover new drug targets linking metabolic and kidney pathways.
- Partnership Enablement: Facilitates the validation and quantification of broader health benefits for partner drugs, such as improvements in kidney function or cardiovascular risk markers.